Iolanda Camerino

Nov 2, 2024 | mdpi.com | Iolanda Camerino |Paola Franco |Adriana Bajetto |Stefano Thellung

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Sep 28, 2023 | mdpi.com | Paola Franco |Iolanda Camerino |Francesco Merlino |Margherita D’Angelo

1. IntroductionGlioblastoma (GBM) is recognized as the most aggressive form of neoplasia of the central nervous system, arising from glia or their precursor cells [1,2]. Although several treatment options are available, including surgery, along with radio- and chemotherapy, GBM is characterized by a very poor prognosis and life expectancy, with a median survival time ranging from 12 to 15 months.